DOCSLIB.ORG

5-Ht2c Serotonin Receptors: Cellular Localization

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
5-Ht2c Serotonin Receptors: Cellular Localization 5-HT2C SEROTONIN RECEPTORS: CELLULAR LOCALIZATION AND CONTROL OF DOPAMINERGIC PATHWAYS IN THE RAT BRAIN By Katherine Demetra Alex Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Thesis Adviser: Dr. Elizabeth A. Pehek Department of Neurosciences CASE WESTERN RESERVE UNIVERSITY January, 2007 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ______________________________________________________ candidate for the Ph.D. degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. 2 Table of Contents: List of Tables 4 List of Figures 5-6 Acknowledgements 7 Abstract 8-9 Chapter 1: Introduction 10-37 Introduction to Dopamine 10-13 Introduction to Serotonin 13-14 Evidence for Serotonergic Control of DA Activity 15-31 Roles of 5-HT2 Receptors in Modulating DA Activity 15-16 5-HT2A 16-21 Localization 16-18 Nigrostriatal Pathway 18 Mesolimbic Pathway 18-19 Mesocortical Pathway 19-21 Summary 21 5-HT2B 21 5-HT2C 21-30 Localization 21-22 Nigrostriatal Pathway 22-26 Mesolimbic Pathway 26-28 Mesocortical Pathway 28-29 Summary 29-30 Summary and Implications 30-31 The Unique Importance of the 5-HT2C Receptor 31-37 Chapter 2: Modulation of Dopamine Release by Striatal 5-HT2C Receptors 38-63 Summary 38 Introduction 39-41 Methods 41-47 Results 47-50 Discussion 50-56 Figures 57-63 Chapter 3: Colocalization of 5-HT2C Receptors and 5-HT2A Receptors in Rat Cortex and Hippocampus 64-92 Summary 64 Introduction 65-69 Methods 69-72 Results 72-74 Discussion 74-81 Figures 82-92 3 Chapter 4: Discussion 93-116 Using Microdialysis to Measure Changes in DA Release 93-95 Differential Regulation of the Nigrostriatal and Mesocortical Pathways 95-96 Tonic Inhibition of DA by 5-HT2C Receptors may be GABA-Mediated 96-98 The Heterogeneous Composition of the Striatum 98-100 Elucidating the Circuitry Involved in Control of DA by Striatal 5-HT2C Receptors 100-106 Cellular Localization of 5-HT2C Receptors in the Cortex and Hippocampus 106-111 Clinical Implications 111-113 Summary 113-114 Figures 115-116 Bibliography: 117-154 4 List of Tables: Table 1: Quantification of 5-HT2C Receptors with Parvalbumin and 5-HT2A Receptors in the Cortex and Hippocampus 92 5 List of Figures: Chapter 2: Figure 1: Intrastriatal Administration of a 5-HT2C Receptor Inverse Agonist Increases Dialysate Dopamine in the Striatum of the Rat 57-58 Figure 2: Coadministration of a 5-HT2C Receptor Agonist Attenuates the 5-HT2C Receptor Inverse Agonist-Induced Increase in Striatal Dopamine 59-60 Figure 3: Intracortical Administration of Low Concentrations of a 5-HT2C Receptor Inverse Agonist does not Affect Dialysate Dopamine in the Prefrontal Cortex 61 Figure 4: Intracortical Administration of Higher Concentrations of a 5-HT2C Receptor Inverse Agonist does not Affect Basal or High K+-Stimulated Dopamine Release in the Prefrontal Cortex 62-63 Chapter 3: Figure 1: Western Blot Illustrating the Specificity of the 5-HT2C Receptor Antibody 82 Figure 2: Immunofluorescence in Cultured Cells 83 Figure 3: 5-HT2C Receptors in Rat Choroid Plexus 84 Figure 4: Regions of Cortex Examined 85 Figure 5: Lack of Colocalization of 5-HT2C Receptors with Parvalbumin in the Cortex of the Rat 86 Figure 6: Lack of Colocalization of 5-HT2C Receptors with Parvalbumin in the Hippocampus of the Rat 87 Figure 7: Rostro-Caudal Level of Hippocampus Examined 88 Figure 8: 5-HT2C Receptors Colocalize with 5-HT2A Receptors in Rat Cortex 89 Figure 9: 5-HT2C Receptors Colocalize with 5-HT2A Receptors in Rat Hippocampus 90 6 Figure 10: 5-HT2C do not Colocalize with GAD65/67 in the Rat Striatum 91 Chapter 4: Figure 1: Putative circuitry of the regulation of nigrostriatal DA by 5-HT2C receptors under basal conditions 115 Figure 2: Putative circuitry of the regulation of nigrostriatal DA by 5-HT2C receptors in the presence of SB 206553 116 7 Acknowledgements: This work was supported by grant MH52220 from the National Institute of Health and a Merit Review Award from the Department of Veterans Affairs to E.A.P. I wish to thank SmithKline and Beecham for their generous donation of SB 206553. I would also like to acknowledge the data contributions of Gregory Yavanian, Hewlett McFarlane, Charlie Pluto, and Atheir Abbas. I would like to acknowledge the support that I have received from my advisor, Dr. Elizabeth Pehek throughout the past 6 years. I would also like to thank the members of my thesis committee for providing constructive criticism and support. In addition, I would like to thank Dr. Bryan Roth for his mentoring and technical help during the collection of my immunofluorescence data. I am grateful to the colleagues that I have worked with in both the Pehek and the Roth laboratories. Lastly, I would like to thank my friends and family for their encouragement and support during this time. 8 5-HT2C Serotonin Receptors: Cellular Localization and Control of Dopaminergic Pathways in the Rat Brain Abstract By Katherine Demetra Alex Dopamine (DA) is known to play a role in the pathology and/or treatment of schizophrenia, drug abuse and Parkinson’s disease. Serotonin (5-HT) is capable of modulating dopamine release through actions at 5-HT receptors. In particular, 5-HT2 receptor binding, and subsequent effects on DA release, may be involved in the efficacy of atypical antipsychotic drugs and recent work suggests that they may be promising targets for the treatment of depression, anxiety, obesity, and drug abuse as well. 5-HT2C receptors have been shown to tonically inhibit DA release in the striatum and the prefrontal cortex (PFC). The localization of the receptors that mediate these effects has not been studied. These data show that 5-HT2C receptors in the terminal region of the nigrostriatal pathway are, at least in part, responsible for the tonic inhibition of DA release in the striatum. In addition, data is presented that suggests that the mesocortical pathway is not modulated by 5-HT2C receptors in the terminal region. The cellular localization of 5-HT2C receptors has not been extensively studied, in part due to a lack of specific antibodies. Here, a selective 5-HT2C receptor antibody was used in immunofluorescence studies to examine the cellular localization of the 5-HT2C receptors that mediate the tonic inhibition of DA release in the brain. These studies show that 5- HT2C receptors do not colocalize with markers for parvalbumin-containing GABAergic cells in the cortex and hippocampus. Importantly 5-HT2C receptors show a high degree of 9 colocalization with 5-HT2A receptors in these regions. 5-HT2A and 5-HT2C receptors are similar in structure and couple to the same intracellular signaling pathways upon activation. Differences in their levels of constitutive activity and desensitization in response to chronic ligand exposure have, however, been shown. Thus, by these mechanisms 5-HT2A and 5-HT2C receptors expressed in the same cortical and hippocampal pyramidal neurons may finely tune cortical efferents. The results presented here have implications for the development of new therapeutics for the treatment of diseases and disorders in which a 5-HT2 receptor-mediated manipulation of DA is beneficial. 10 CHAPTER 1: Introduction to Dopamine: The first known function of dopamine (DA) was its role in many species as a precursor to norepinephrine (NE) and epinephrine – the other neurotransmitters in the catecholamine family. It wasn’t until the late 1950’s that evidence began to accumulate favoring an independent role for DA in the brain. At this time it was discovered that DA and NE were manufactured in different brain regions, in essence the regions with the highest levels of DA produced low levels of NE and vice versa (Bertler and Rosengren, 1958; Carlsson, 1959) and that in mammals the vast majority of the body’s DA is found in the brain (Carlsson, 1959). Further research led to the discovery of dopaminergic pathways in which cell bodies in one brain region send projections to another brain region where DA is released from axon terminals. The first to be characterized was the nigrostriatal pathway in which cell bodies in the substantia nigra pars compacta (SNpc) project their axons to the caudate and putamen, collectively called the striatum (Anden et al., 1964). Soon after, two additional pathways had been discovered: the mesolimbic pathway in which cell bodies in the ventral tegmental area (VTA) project axons to the nucleus accumbens (NA), and the tuberoinfundibular pathway in which cell bodies in the arcuate nucleus of the hypothalamus project axons to the median eminence (for review see McClure, 1973; Glowinski, 1975). Later, evidence was found for a fourth group of neurons, dubbed the mesocortical pathway, that send dopaminergic projections from the VTA to the cerebral cortex, specifically the prefrontal cortex (PFC) (Glowinski, 1975). DA has binding affinity for and adrenergic receptors and it was not until it was recognized that DA has a distinct pattern of expression from NE that it became apparent that there are also distinct DA receptors (see Woodruff, 1971 for review). It is 11 now known that there are 5 distinct DA receptor subtypes which can be classified as D1- like (D1 and D5) and D2-like (D2, D3, and D4) based on their coupling to G-protein signal cascades. D1-like receptors couple positively to adenylyl cyclase while D2-like receptors couple negatively to adenylyl cyclase and thus cAMP production (for review, see Missale et al., 1998). DA receptors are found in both the cell body and terminal regions of the dopaminergic pathways. Both D1-like and D2-like receptor subtypes are found both pre and postsynaptically but only D2 receptors are known to serve as autoreceptors (see Missale et al., 1998, for review and Paspalas and Goldman-Rakic, 2005).
Load more

Recommended publications
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • Neuromodulators and Long-Term Synaptic Plasticity in Learning and Memory: a Steered-Glutamatergic Perspective
    brain sciences Review Neuromodulators and Long-Term Synaptic Plasticity in Learning and Memory: A Steered-Glutamatergic Perspective Amjad H. Bazzari * and H. Rheinallt Parri School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)1212044186 Received: 7 October 2019; Accepted: 29 October 2019; Published: 31 October 2019 Abstract: The molecular pathways underlying the induction and maintenance of long-term synaptic plasticity have been extensively investigated revealing various mechanisms by which neurons control their synaptic strength. The dynamic nature of neuronal connections combined with plasticity-mediated long-lasting structural and functional alterations provide valuable insights into neuronal encoding processes as molecular substrates of not only learning and memory but potentially other sensory, motor and behavioural functions that reflect previous experience. However, one key element receiving little attention in the study of synaptic plasticity is the role of neuromodulators, which are known to orchestrate neuronal activity on brain-wide, network and synaptic scales. We aim to review current evidence on the mechanisms by which certain modulators, namely dopamine, acetylcholine, noradrenaline and serotonin, control synaptic plasticity induction through corresponding metabotropic receptors in a pathway-specific manner. Lastly, we propose that neuromodulators control plasticity outcomes through steering glutamatergic transmission, thereby gating its induction and maintenance. Keywords: neuromodulators; synaptic plasticity; learning; memory; LTP; LTD; GPCR; astrocytes 1. Introduction A huge emphasis has been put into discovering the molecular pathways that govern synaptic plasticity induction since it was first discovered [1], which markedly improved our understanding of the functional aspects of plasticity while introducing a surprisingly tremendous complexity due to numerous mechanisms involved despite sharing common “glutamatergic” mediators [2].
    [Show full text]
  • Multiplexed Neurochemical Signaling by Neurons of the Ventral Tegmental
    Journal of Chemical Neuroanatomy 73 (2016) 33–42 Contents lists available at ScienceDirect Journal of Chemical Neuroanatomy journal homepage: www.elsevier.com/locate/jchemneu Multiplexed neurochemical signaling by neurons of the ventral tegmental area David J. Barker, David H. Root, Shiliang Zhang, Marisela Morales* Neuronal Networks Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse, 251 Bayview Blvd Suite 200, Baltimore, MD 21224, United States A R T I C L E I N F O A B S T R A C T Article history: The ventral tegmental area (VTA) is an evolutionarily conserved structure that has roles in reward- Received 26 June 2015 seeking, safety-seeking, learning, motivation, and neuropsychiatric disorders such as addiction and Received in revised form 31 December 2015 depression. The involvement of the VTA in these various behaviors and disorders is paralleled by its Accepted 31 December 2015 diverse signaling mechanisms. Here we review recent advances in our understanding of neuronal Available online 4 January 2016 diversity in the VTA with a focus on cell phenotypes that participate in ‘multiplexed’ neurotransmission involving distinct signaling mechanisms. First, we describe the cellular diversity within the VTA, Keywords: including neurons capable of transmitting dopamine, glutamate or GABA as well as neurons capable of Reward multiplexing combinations of these neurotransmitters. Next, we describe the complex synaptic Addiction Depression architecture used by VTA neurons in order to accommodate the transmission of multiple transmitters. Aversion We specifically cover recent findings showing that VTA multiplexed neurotransmission may be mediated Co-transmission by either the segregation of dopamine and glutamate into distinct microdomains within a single axon or Dopamine by the integration of glutamate and GABA into a single axon terminal.
    [Show full text]
  • Midbrain Dopaminergic and Gabaergic Neurons' Responses To
    Institute of Zoology and Biomedical Research Topic: Midbrain dopaminergic and GABAergic neurons' responses to the aversive stimulus across alternating brain states of urethane anaesthetized rat - electrophysiological in vivo studies. Supervisor: dr hab. Tomasz Błasiak (Department of Neurophysiology and Chronobiology) [email protected] Background information: Ventral tegmental area (VTA) is one of the main sources of dopamine (DA) in the mammalian brain. This structure is the centre of dopaminergic pathways and plays a key role in regulation of motivation (Wise, 2005), goaldirected behaviours, reinforcement learning or reacting to reward-related cues (Schultz, 1997; Morita, 2013). Better understanding of how DA circuits work and are modulated can contribute to explanation of mechanisms of dysfunctions laying at the root of some nervous system disorders such as addiction, anxiety, PTSD or some of depression symptoms (anhedonia or lack of motivation). It has been shown that, occurrence of unexpected reward, reward-related cue or novelty causes phasic release of DA in VTA target structures (Goto et al, 2007). Those phasic changes in DA neurons activity lie at the root of forming reward prediction error (RPE) signal which encodes difference between expected and delivered reward - updating reward expectations and forming the basis for learning (Schultz, 2016). DA neurons also code response to the aversive or noxious stimuli by development of quick, short latency pause in firing. For a long time, it has been assumed that DA neurons code both reward and aversive stimuli homogenously across the entire dopaminergic neurons population forming positive and negative prediction error signals respectively (Schultz, 1998; Ungless et al., 2004).
    [Show full text]
  • Electrophysiological and Morphological Evidence for a Gabaergic Nigrostriatal Pathway
    The Journal of Neuroscience, June 1, 1999, 19(11):4682–4694 Electrophysiological and Morphological Evidence for a GABAergic Nigrostriatal Pathway Manuel Rodrı´guez1 and Toma´ s Gonza´ lez-Herna´ ndez2 Departments of 1Physiology and 2Anatomy, Faculty of Medicine, University of La Laguna, La Laguna, Tenerife, Canary Islands, Spain The electrophysiological and neurochemical characteristics of gic neurons, a percentage that reached 81–84% after 6-OHDA the nondopaminergic nigrostriatal (NO-DA) cells and their func- injection. Electrophysiologically, NO-DA cells showed a behavior tional response to the degeneration of dopaminergic nigrostri- similar to that found in other nigral GABAergic (nigrothalamic) atal (DA) cells were studied. Three different criteria were used to cells. In addition, the 6-OHDA degeneration of DA cells induced a identify NO-DA cells: (1) antidromic response to striatal stimu- modification of their electrophysiological pattern similar to that lation with an electrophysiological behavior (firing rate, inter- found in GABAergic nigrothalamic neurons. Taken together, the spike interval variability, and conduction velocity) different from present data indicate the existence of a small GABAergic nigro- that of DA cells; (2) retrograde labeling after striatal injection of striatal pathway and suggest their involvement in the pathophys- HRP but showing immunonegativity for DA cell markers (ty- iology of Parkinson’s disease. rosine hydroxylase, calretinin, calbindin-D28k, and cholecysto- kinin); and (3) resistance to neurotoxic effect of 6-hydroxydomine Key words: nigrostriatal pathway; dopaminergic cells; (6-OHDA). Our results showed that under normal conditions, GABAergic cells; GABA; glutamic acid decarboxylase; parval- 5–8% of nigrostriatal neurons are immunoreactive for GABA, glu- bumin; calretinin; calbindin-D28k; cholecystokinin; Parkinson’s tamic acid decarboxylase, and parvalbumin, markers of GABAer- disease The substantia nigra (SN) is a major output center of the basal paminergic (Grace and Bunney, 1980, 1983a).
    [Show full text]
  • Optogenetic Activation of Dopamine Neurons in the Ventral Tegmental Area Induces Reanimation from General Anesthesia
    CORE Metadata, citation and similar papers at core.ac.uk Provided by DSpace@MIT Optogenetic activation of dopamine neurons in the ventral tegmental area induces reanimation from general anesthesia Norman E. Taylora,b,c, Christa J. Van Dorta,b,c, Jonathan D. Kennya,c, JunZhu Peia,c, Jennifer A. Guideraa,c, Ksenia Y. Vlasova,c, Justin T. Leea,c, Edward S. Boydenc,d,e,f, Emery N. Browna,b,c,g,h,1,2, and Ken Solta,b,c,1 aDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114; bDepartment of Anaesthesia, Harvard Medical School, Boston, MA 02114; cDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139; dMedia Lab, Massachusetts Institute of Technology, Cambridge, MA 02139; eMcGovern Institute, Massachusetts Institute of Technology, Cambridge, MA 02139; fDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; gThe Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139; and hInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139 Contributed by Emery N. Brown, September 14, 2016 (sent for review February 29, 2016; reviewed by Loren M. Frank, Robert W. Gereau, and Andrew Jenkins) Dopamine (DA) promotes wakefulness, and DA transporter inhibi- There are currently no clinically approved pharmacologic or cir- tors such as dextroamphetamine and methylphenidate are effective cuit-level interventions that can induce active emergence or for increasing arousal and inducing reanimation, or active emer- reanimation from general anesthesia (10). Dopamine (DA) is a gence from general anesthesia. DA neurons in the ventral tegmental neurotransmitter that is well-known to elicit wakefulness (11).
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Modulation of Dialysate Levels of Dopamine, Noradrenaline
    Modulation of Dialysate Levels of Dopamine, Noradrenaline, and Serotonin (5-HT) in the Frontal Cortex of Freely-Moving Rats by (-)-Pindolol Alone and in Association with 5-HT Reuptake Inhibitors: Comparative Roles b of -Adrenergic, 5-HT1A, and 5-HT1B Receptors Alain Gobert, Ph.D. and Mark J. Millan, Ph.D. (-)-Pindolol, which possesses significant affinity for 5-HT1A, involved. (-)-Pindolol potentiated the increase in FCX levels b 5-HT1B, and 1/2-adrenergic receptors (AR)s, dose- of 5-HT elicited by the 5-HT reuptake inhibitors, fluoxetine dependently increased extracellular levels of dopamine and duloxetine, and also enhanced their ability to elevate (DA) and noradrenaline (NAD) versus 5-HT, in dialysates FCX levels of DA—though not of NAD. In contrast to of the frontal cortex (FCX), but not accumbens and (-)-pindolol, betaxolol and ICI118,551 did not affect the striatum, of freely-moving rats. In distinction, the actions of fluoxetine, whereas both WAY100,635 and b preferential 1-AR antagonist, betaxolol, and the SB224,289 potentiated the increase in levels of 5-HT—but b preferential 2-AR antagonist, ICI118,551, did not increase not DA or NAD levels—elicited by fluoxetine. In basal levels of DA, NAD, or 5-HT. Further, they both dose- conclusion, (-)-pindolol modulates, both alone and together dependently and markedly blunted the influence of with 5-HT reuptake inhibitors, dopaminergic, adrenergic, (-)-pindolol upon DA and NAD levels. The selective 5-HT1A and serotonergic transmission in the FCX via a complex b receptor antagonist, WAY100,635, slightly attenuated the pattern of actions at 1/2-ARs, 5-HT1A, and 5-HT1B (-)-pindolol-induced increase in DA and NAD levels, while receptors.
    [Show full text]
  • Neuromodulation Shapes Interneuron Communication in the Mouse Striatum
    From DEPARTMENT OF NEUROSCIENCE Karolinska Institutet, Stockholm, Sweden NEUROMODULATION SHAPES INTERNEURON COMMUNICATION IN THE MOUSE STRIATUM Matthijs Constantijn Dorst Stockholm 2020 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by US-AB © Matthijs Constantijn Dorst, 2020 ISBN 978-91-7831-908-4 Neuromodulation shapes interneuron communication in the mouse Striatum THESIS FOR DOCTORAL DEGREE (Ph.D.) By Matthijs Constantijn Dorst Principal Supervisor: Opponent: Professor Gilad Silberberg Professor Hagai Bergman Karolinska Institutet The Hebrew University of Jerusalem Department of Neuroscience Edmond & Lily Safra Center for Brain Sciences Co-supervisor(s): Examination Board: Professor Per Uhlén Professor Per Svenningsson Karolinska Institutet Karolinska Institutet Department of Medical Biochemistry and Department of Clinical Neuroscience Biophysics Division of Neuropharmacology - movement disorders Senior lecturer Karima Chergui Karolinska Institutet Department of Physiology and Pharmacology Division of Molecular Neurophysiology Professor Klas Kullander Uppsala Universitet Department of Neuroscience Research group Formation and Function of Neuronal Circuits Included Studies The following studies are included in this thesis, and will be referenced through- out the text as such: Study 1 Garas, F.N., Shah, R.S., Kormann, E., Doig, N.M., Vinciati, F., Nakamura, K.C., Dorst, M.C., Smith, Y., Magill, P.J. and Sharott, A., 2016. Sec- retagogin expression delineates functionally-specialized populations of striatal parvalbumin-containing interneurons. Elife, 5, p.e16088. Study 2 Lindroos, R., Dorst, M.C., Du, K., Filipović, M., Keller, D., Ketzef, M., Kozlov, A.K., Kumar, A., Lindahl, M., Nair, A.G., Pérez-Fernández, J., Grillner, S., Silberberg, G., Kotaleski, J.H., 2018. Basal Ganglia Neuromodulation Over Multiple Temporal and Structural Scales—Simulations of Direct Pathway MSNs Investigate the Fast Onset of Dopaminergic Effects and Predict the Role of Kv4.
    [Show full text]
  • Dopaminergic Microtransplants Into the Substantia Nigra of Neonatal Rats with Bilateral 6-OHDA Lesions
    The Journal of Neuroscience, May 1995, 15(5): 3548-3561 Dopaminergic Microtransplants into the Substantia Nigra of Neonatal Rats with Bilateral 6-OHDA Lesions. I. Evidence for Anatomical Reconstruction of the Nigrostriatal Pathway Guido Nikkhah,1,2 Miles G. Cunningham,3 Maria A. Cenci,’ Ronald D. McKay,4 and Anders Bj6rklund’ ‘Department of Medical Cell Research, University of Lund, S-223 62 Lund, Sweden, *Neurosurgical Clinic, Nordstadt Hospital, D-301 67 Hannover, Germany, 3Harvard Medical School, Boston, Massachusetts 02115, and 4 Laboratory of Molecular Biology, NINDS NIH, Bethesda, Maryland 20892 Reconstruction of the nigrostriatal pathway by long axon [Key words: target reinnervation, axon growth, neural growth derived from dopamine-rich ventral mesencephalic transplantation, tyrosine hydroxylase immunohistochem- (VM) transplants grafted into the substantia nigra may en- istry, Fos protein, Fluoro-Gold] hance their functional integration as compared to VM grafts implanted ectopically into the striatum. Here we report on In the lesioned brain of adult recipients dopamine-rich grafts a novel approach by which fetal VM grafts are implanted from fetal ventral mesencephalon (VM) are unable to reinner- unilaterally into the substantia nigra (SN) of 6-hydroxydo- vate the caudate-putamen unless they are placed close to, or pamine (SOHDA)-lesioned neonatal pups at postnatal day within, the denervated target structure (BjGrklund et al., 1983b; 3 (P3) using a microtransplantation technique. The results Nikkhah et al., 1994b). The failure of regenerating dopaminergic demonstrate that homotopically placed dopaminergic neu- axons to reinnervate the striatum from more distant implantation rons survive and integrate well into the previously sites, including their normal site of origin, the substantia nigra 6-OHDA-lesioned neonatal SN region.
    [Show full text]
  • Neuromelanin-Sensitive MRI As a Noninvasive Proxy Measure of Dopamine Function in the Human Brain
    Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain Clifford M. Cassidya,b,1, Fabio A. Zuccac, Ragy R. Girgisa, Seth C. Bakera, Jodi J. Weinsteina,d, Madeleine E. Sharpe,f, Chiara Belleic, Alice Valmadrec, Nora Vanegase, Lawrence S. Kegelesa, Gary Brucatoa, Un Jung Kange, David Sulzera,e, Luigi Zeccaa,c, Anissa Abi-Darghama,d, and Guillermo Horgaa,1 aDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY 10032; bUniversity of Ottawa Institute of Mental Health Research, affiliated with The Royal, Ottawa, ON K1Z 8N3, Canada; cInstitute of Biomedical Technologies, National Research Council of Italy, Segrate, 20090 Milan, Italy; dDepartment of Psychiatry, Stony Brook University, Stony Brook, NY 11794; eDepartment of Neurology, Columbia University Medical Center, New York, NY 10032; and fDepartment of Neurology and Neurosurgery, McGill University, Montreal, QC H3A 2B4, Canada Edited by Marcus E. Raichle, Washington University in St. Louis, St. Louis, MO, and approved January 22, 2019 (received for review May 9, 2018) Neuromelanin-sensitive MRI (NM-MRI) purports to detect the are only cleared from tissue following cell death through the content of neuromelanin (NM), a product of dopamine metabolism action of microglia, as in neurodegenerative conditions such as that accumulates with age in dopamine neurons of the substantia PD (5, 6). Given that NM–iron complexes are paramagnetic (6, nigra (SN). Interindividual variability in dopamine function may 7), they can be imaged using MRI (8–11). A family of MRI se- result in varying levels of NM accumulation in the SN; however, quences, known as NM-MRI, captures groups of neurons with the ability of NM-MRI to measure dopamine function in non- high NM content, such as those in the SN, as hyperintense re- neurodegenerative conditions has not been established.
    [Show full text]
  • Prominence of the Dopamine D2 Short Isoform in Dopaminergic Pathways
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 7731–7736, June 1998 Neurobiology Prominence of the dopamine D2 short isoform in dopaminergic pathways ZAFAR U. KHAN*†,LADISLAV MRZLJAK*, ANTONIA GUTIERREZ‡,ADELAIDA DE LA CALLE‡, AND PATRICIA S. GOLDMAN-RAKIC* *Section of Neurobiology, Yale University School of Medicine, New Haven, CT 06510; and ‡Department of Cell Biology, University of Malaga, Malaga 29071, Spain Contributed by P. S. Goldman-Rakic, April 15, 1998 ABSTRACT As a result of alternative splicing, the D2 gene opment. Affinity purification of the antisera was as described of the dopamine receptor family exists in two isoforms. The D2 elsewhere (12). In brief, peptide (5 mg) was coupled to1gof long is characterized by the insertion of 29 amino acids in the activated thiopropyl-Sepharose 6B (Pharmacia LKB). Phos- third cytoplasmic loop, which is absent in the short isoform. We phate-buffered saline (PBS) diluted antiserum (1:5) was circu- have produced subtype-specific antibodies against both the D2 lated through the column. After washing with PBS, the antibody short and D2 long isoforms and found a unique compartmen- was eluted with glycinezHCl, pH 2.3, and dialyzed against PBS. talization between these two isoforms in the primate brain. The Membrane Preparation. Adult rhesus monkey (Macaca mu- D2 short predominates in the cell bodies and projection axons of latta) brains were used for the preparation of tissue membranes the dopaminergic cell groups of the mesencephalon and hypo- as described earlier (13). Briefly, brain tissues were homogenized thalamus, whereas the D2 long is more strongly expressed by with 10% sucrose in TriszHCl, pH 7.4, and centrifuged at 3,000 neurons in the striatum and nucleus accumbens, structures rpm in a Sorvall for 5 min.
    [Show full text]